Brokers Offer Predictions for VRAX FY2025 Earnings

Virax Biolabs Group Limited (NASDAQ:VRAX) – Equities researchers at HC Wainwright issued their FY2025 earnings estimates for Virax Biolabs Group in a report issued on Monday, March 31st. HC Wainwright analyst Y. Chen forecasts that the company will earn ($1.48) per share for the year. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. HC Wainwright also issued estimates for Virax Biolabs Group’s Q4 2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.18) EPS and FY2026 earnings at ($1.01) EPS.

Virax Biolabs Group Stock Up 3.8 %

Shares of VRAX opened at $1.14 on Thursday. Virax Biolabs Group has a 12-month low of $0.60 and a 12-month high of $9.00. The business has a 50-day simple moving average of $1.59 and a two-hundred day simple moving average of $1.88.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd bought a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned about 0.37% of Virax Biolabs Group at the end of the most recent reporting period. Institutional investors own 8.61% of the company’s stock.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.